Managed Healthcare Executive March 5, 2024
Biotech companies and researchers are investigating whether psychedelics could be used to treat a variety of mental health problems, including post-traumatic stress disorder and depression.
After going dormant for decades because of government restrictions, research focusing on the use of psychedelics for the treatment of psychiatric conditions has sprung to life. Research conducted in this area in the 1950s and 1960s — remember Timothy Leary? — came to a screeching halt with President Richard Nixon’s declaration of a war on drugs and the passing of the Controlled Substances Act of 1970. Hallucinogens and psychedelics were classified as Schedule I substances, defining them as having high abuse potential and no medically accepted uses.
In 1992, meetings between the National Institute on...
Today's Sponsors
Today's Sponsor